Cumulus Oncology Ltd. has announced key milestones, in partnership with collaborator Leadxpro AG, in the companies’ protein structure-driven GPR68 drug discovery project.

Immunesensor Therapeutics Inc. has received Human Research Ethics Committee (HREC) approval and clinical trial notification (CTN) clearance by Australia’s Therapeutic Goods Administration (TGA) to initiate a phase I study of IMSB-301, a novel, orally available small-molecule cGAS inhibitor that is being developed for the treatment of inflammatory and autoimmune diseases.

Kalm Therapeutics Inc. disclosed a $700,000 oversubscribed closing of its seed round, which will be used to complete regulatory activities outlined in Kalm’s pre-IND meeting with the U.S. FDA, fund personnel and transfer the company’s patch production to a manufacturer.

Hepatic ischemia-reperfusion injury (HIRI) is a common leading cause of liver injury and is associated with several clinical conditions, including liver transplantation, liver resection surgeries and cancer, among others.

Liver fibrosis still lacks effective therapy; hepatic stellate cells (HSCs) are the primary fibrogenic cell type activated during liver injury. To date, almost half of the drugs used for liver treatment are natural product derivatives.

AAT-076 was tested in the preclinical setting for its analgesic potential in COX-1 and COX-2 assays, as well as in in vivo rat models of air pouch inflammation, adjuvant-induced arthritis and neuropathic pain models. The compound was selected as a candidate analgesic compound due to its effective COX-2 inhibition within the central nervous system.

Tr1x Inc. has announced that the FDA has cleared its IND application for its engineered Tr1 Treg cell therapy TRX-103 for treatment-refractory Crohn’s disease.